Marcos António Gomes

Marcos António Gomes

Auto-generated profile, based on publicly available information

Marcos António Gomes

Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2017 in Brain
Verified
Journal Article
Open access
PDF file
Hugo Vicente MirandaHugo Vicente Miranda
Hugo Vicente Miranda
ÉSÉva M. Szegő
Éva M. Szegő
LOLuís M. A. Oliveira
Luís M. A. Oliveira
CBCarlo Breda
Carlo Breda
EDEkrem Darendelioglu
Ekrem Darendelioglu
Tiago OuteiroTiago Outeiro
Tiago Outeiro
α-Synuclein misfolding and aggregation is a hallmark in Parkinson’s disease and in several other neurodegenerative diseases known as synucleinopathies. The toxic properties of α-synuclein are conserved from yeast to man, but the precise underpinnings of the cellular pathologies associated are still elusive, complicating the development of effective therapeutic strategies. Combining molecular genetics with target-based approaches, we established that glycation, an unavoidable age-associated post-translational modification, enhanced α-synuclein toxicity in vitro and in vivo, in Drosophila and in mice. Glycation affected primarily the N-terminal region of α-synuclein, reducing membrane binding, impaired the clearance of α-synuclein, and promoted the accumulation of toxic oligomers that impaired neuronal synaptic transmission. Strikingly, using glycation inhibitors, we demonstrated that normal clearance of α-synuclein was re-established, aggregation was reduced, and motor phenotypes in Drosophila were alleviated. Altogether, our study demonstrates glycation constitutes a novel drug target that can be explored in synucleinopathies as well as in other neurodegenerative conditions.

22 July 2020 in Nature
Verified
Journal Article
Closed access
PDF file
YLYinqing Li
Yinqing Li
VLVioleta G. Lopez-Huerta
Violeta G. Lopez-Huerta
XAXian Adiconis
Xian Adiconis
KLKirsten Levandowski
Kirsten Levandowski
SCSoonwook Choi
Soonwook Choi
GFGuoping Feng
Guoping Feng

20 October 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Hugo Vicente MirandaHugo Vicente Miranda
Hugo Vicente Miranda
RCRafaela Cássio
Rafaela Cássio
LCLeonor Correia-Guedes
Leonor Correia-Guedes
MGMarcos António Gomes
Marcos António Gomes
Ana ChegãoAna Chegão
Ana Chegão
Tiago OuteiroTiago Outeiro
Tiago Outeiro
Parkinson’s disease (PD) is a progressive neurodegenerative disorder known for the typical motor features associated. Pathologically, it is characterized by the intracellular accumulation of alpha-synuclein (aSyn) in Lewy bodies and Lewy neurites. Currently, there are no established biochemical markers for diagnosing or for following disease progression, a major limitation for the clinical practice. Posttranslational modifications (PTMs) in aSyn have been identified and implicated on its pathobiology. Since aSyn is abundant in blood erythrocytes, we aimed to evaluate whether PTMs of aSyn in the blood might hold value as a biomarker for PD. We examined 58 patients with PD and 30 healthy age-matched individuals. We found that the levels of Y125 phosphorylated, Y39 nitrated, and glycated aSyn were increased in PD, while those of SUMO were reduced. A combinatory analysis of the levels of these PTMs resulted in an increased sensitivity, with an area under curve (AUC) of 0.843 for PD versus healthy controls, and correlated with disease severity and duration. We conclude that the levels of these selected PTMs hold strong potential as biochemical markers for PD. Ultimately, our findings might facilitate the monitoring of disease progression in clinical trials, opening the possibility for developing more effective therapies against PD.

1 November 2017 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
LGLeonor Correia Guedes
Leonor Correia Guedes
RCRobin Barry Chan
Robin Barry Chan
MGMarcos António Gomes
Marcos António Gomes
VCVasco A. Conceição
Vasco A. Conceição
RMRaquel Bouça Machado
Raquel Bouça Machado
GMGabriel Miltenberger-Miltenyi
Gabriel Miltenberger-Miltenyi

18 November 2016 in Scientific Reports
Verified
Journal Article
Open access
Hugo Vicente MirandaHugo Vicente Miranda
Hugo Vicente Miranda
MGMarcos António Gomes
Marcos António Gomes
JBJoana Branco-Santos
Joana Branco-Santos
CBCarlo Breda
Carlo Breda
DLDiana F. Lázaro
Diana F. Lázaro
Tiago OuteiroTiago Outeiro
Tiago Outeiro
Protein glycation is an age-dependent posttranslational modification associated with several neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. By modifying amino-groups, glycation interferes with folding of proteins, increasing their aggregation potential. Here, we studied the effect of pharmacological and genetic manipulation of glycation on huntingtin (HTT), the causative protein in Huntington’s disease (HD). We observed that glycation increased the aggregation of mutant HTT exon 1 fragments associated with HD (HTT72Q and HTT103Q) in yeast and mammalian cell models. We found that glycation impairs HTT clearance thereby promoting its intracellular accumulation and aggregation. Interestingly, under these conditions autophagy increased and the levels of mutant HTT released to the culture medium decreased. Furthermore, increased glycation enhanced HTT toxicity in human cells and neurodegeneration in fruit flies, impairing eclosion and decreasing life span. Overall, our study provides evidence that glycation modulates HTT exon-1 aggregation and toxicity, and suggests it may constitute a novel target for therapeutic intervention in HD.

17 June 2010 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
MSM. Schuchardt
M. Schuchardt
MTM. Toelle
M. Toelle
THT. Huang
T. Huang
AWA. Wiedon
A. Wiedon
MGM. Van Der Giet
M. Van Der Giet
BOBoyett
Boyett
Purpose: MMP-9 is the prominent isozyme of matrix metalloproteinases (MMP) known to be highly expressed in human atherosclerotic plaques. One potent inhibitor of MMP-9 production is the transforming growth factor beta (TGF-β). Similar to this, we also observed inhibitory effects with sphingosine 1-phosphate (S1P), accumulation in high density lipoprotein (HDL), which presumably suppresses MMP-9 production. The aim of this study was to reveal the inhibitory influence of HDL on MMP-9 production and the molecular mechanisms behind these processes.